ClinVar Miner

Submissions for variant NM_000251.3(MSH2):c.1771_1772insA (p.Pro591fs)

dbSNP: rs267607977
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
International Society for Gastrointestinal Hereditary Tumours (InSiGHT) RCV000076280 SCV000107301 pathogenic Lynch syndrome 2013-09-05 reviewed by expert panel research Coding sequence variation introducing premature termination codon
Invitae RCV000524359 SCV000548142 pathogenic Hereditary nonpolyposis colorectal neoplasms 2021-07-01 criteria provided, single submitter clinical testing This sequence change inserts 1 nucleotide in exon 12 of the MSH2 mRNA (c.1771_1772insA), causing a frameshift at codon 591. This creates a premature translational stop signal (p.Pro591Hisfs*7) and is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH2 are known to be pathogenic. This particular variant has been reported in the literature in an individual affected with Lynch syndrome (PMID: 12362047). For these reasons, this variant has been classified as Pathogenic.
Ambry Genetics RCV001013055 SCV001173592 pathogenic Hereditary cancer-predisposing syndrome 2018-09-30 criteria provided, single submitter clinical testing The c.1771_1772insA pathogenic mutation, located in coding exon 12 of the MSH2 gene, results from an insertion of one nucleotide at position 1771, causing a translational frameshift with a predicted alternate stop codon (p.P591Hfs*7). This mutation has been previously identified in a Polish cohort of HNPPC/Lynch syndrome kindreds (Kurzawski G et al. J. Med. Genet. 2002 Oct;39:E65; Kurzawski G et al. Clin. Genet. 2006 Jan;69:40-7; Kurzawski G et al. J. Biochem. Biophys. Methods. 2002 Mar;51:89-100; Kurzawski G. Hered Cancer Clin Pract, 2006 Dec;4:197-205). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.